|
1
|
Mitobe Y, Takayama KI, Horie-Inoue K and
Inoue S: Prostate cancer-associated lncRNAs. Cancer Lett.
418:159–166. 2018. View Article : Google Scholar
|
|
2
|
Misawa A, Takayama KI and Inoue S: Long
non-coding RNAs and prostate cancer. Cancer Sci. 108:2107–2114.
2017. View Article : Google Scholar
|
|
3
|
Chang AJ, Autio KA, Roach M III and Scher
HI: High-risk prostate cancer-classification and therapy. Nat Rev
Clin Oncol. 11:308–323. 2014. View Article : Google Scholar
|
|
4
|
Chi Y, Wang D, Wang J, Yu W and Yang J:
Long non-coding RNA in the pathogenesis of cancers. Cells.
8:10152019. View Article : Google Scholar
|
|
5
|
Ponting CP, Oliver PL and Reik W:
Evolution and functions of long noncoding RNAs. Cell. 136:629–641.
2009. View Article : Google Scholar
|
|
6
|
Zhang Y, Pitchiaya S, Cieslik M, Niknafs
YS, Tien JCY, Hosono Y, Iyer MK, Yazdani S, Subramaniam S, Shukla
SK, et al: Analysis of the androgen receptor-regulated lncRNA
landscape identifies a role for ARLNC1 in prostate cancer
progression. Nat Genet. 50:814–824. 2018. View Article : Google Scholar
|
|
7
|
Zhang A, Zhao JC, Kim J, Fong KW, Yang YA,
Chakravarti D, Mo YY and Yu J: LncRNA HOTAIR enhances the
androgen-receptor-mediated transcriptional program and drives
castration-resistant prostate cancer. Cell Rep. 13:209–221. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gu P, Chen X, Xie R, Han J, Xie W, Wang B,
Dong W, Chen C, Yang M, Jiang J, et al: lncRNA HOXD-AS1 regulates
proliferation and chemo-resistance of castration-resistant prostate
cancer via recruiting WDR5. Mol Ther. 25:1959–1973. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun M, Geng D, Li S, Chen Z and Zhao W:
LncRNA PART1 modulates toll-like receptor pathways to influence
cell proliferation and apoptosis in prostate cancer cells. Biol
Chem. 399:387–395. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shang Z, Yu J, Sun L, Tian J, Zhu S, Zhang
B, Dong Q, Jiang N, Flores-Morales A, Chang C and Niu Y: LncRNA
PCAT1 activates AKT and NF-κB signaling in castration-resistant
prostate cancer by regulating the PHLPP/FKBP51/IKKα complex.
Nucleic Acids Res. 47:4211–4225. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu M, Huang Y, Chen T, Wang W, Yang S, Ye
Z and Xi X: LncRNA MEG3 inhibits the progression of prostate cancer
by modulating miR-9-5p/QKI-5 axis. J Cell Mol Med. 23:29–38. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hua JT, Chen S and He HH: Landscape of
noncoding RNA in prostate cancer. Trends Genet. 35:840–851. 2019.
View Article : Google Scholar
|
|
13
|
Shuai Y, Ma Z, Liu W, Yu T, Yan C, Jiang
H, Tian S, Xu T and Shu Y: TEAD4 modulated LncRNA MNX1-AS1
contributes to gastric cancer progression partly through
suppressing BTG2 and activating BCL2. Mol Cancer. 19:62020.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chu J, Li H, Xing Y, Jia J, Sheng J, Yang
L, Sun K, Qu Y, Zhang Y, Yin H, et al: LncRNA MNX1-AS1 promotes
progression of esophageal squamous cell carcinoma by regulating
miR-34a/SIRT1 axis. Biomed Pharmacother. 116:1090292019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gao Y, Xu Y, Wang J, Yang X, Wen L and
Feng J: lncRNA MNX1-AS1 promotes glioblastoma progression through
inhibition of miR-4443. Oncol Res. 27:341–347. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu X, Yang Q, Yan J, Zhang X and Zheng M:
LncRNA MNX1-AS1 promotes the progression of cervical cancer through
activating MAPK pathway. J Cell Biochem. 120:4268–4277. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu G, Guo X, Zhang Y, Liu Y, Li D, Tang G
and Cui S: Expression and significance of LncRNA MNX1-AS1 in
non-small cell lung cancer. Onco Targets Ther. 12:3129–3138. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li Z, Wang F and Zhang S: Knockdown of
lncRNA MNX1-AS1 suppresses cell proliferation, migration, and
invasion in prostate cancer. FEBS Open Bio. 9:851–858. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42:D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng A, Song X, Zhang L, Zhao L, Mao X,
Wei M and Jin F: Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis
regulates breast cancer stemness via wnt/β-catenin pathway. J Exp
Clin Cancer Res. 38:3052019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pritt SL and Smith TM: Institutional
animal care and use committee postapproval monitoring programs: A
proposed comprehensive classification scheme. J Am Assoc Lab Anim
Sci. 59:127–131. 2020. View Article : Google Scholar
|
|
23
|
Ji D, Wang Y, Sun B, Yang J and Luo X:
Long non-coding RNA MNX1-AS1 promotes hepatocellular carcinoma
proliferation and invasion through targeting miR-218-5p/COMMD8
axis. Biochem Biophys Res Commun. 513:669–674. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li J, Li Q, Li D, Shen Z, Zhang K, Bi Z
and Li Y: Long non-coding RNA MNX1-AS1 promotes progression of
triple negative breast cancer by enhancing phosphorylation of
Stat3. Front Oncol. 10:11082020. View Article : Google Scholar
|
|
25
|
Liu H, Han L, Liu Z and Gao N: Long
noncoding RNA MNX1-AS1 contributes to lung cancer progression
through the miR-527/BRF2 pathway. J Cell Physiol. 234:13843–13850.
2019. View Article : Google Scholar
|
|
26
|
Lv Y, Li H, Li F, Liu P and Zhao X: Long
noncoding RNA MNX1-AS1 knockdown inhibits cell proliferation and
migration in ovarian cancer. Cancer Biother Radiopharm. 32:91–99.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang J, Xing H, Nikzad AA, Liu B, Zhang Y,
Li S, Zhang E and Jia Z: Long noncoding RNA MNX1 antisense RNA 1
exerts oncogenic functions in bladder cancer by regulating
miR-218-5p/RAB1A axis. J Pharmacol Exp Ther. 372:237–247. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang W, Huang L, Lu X, Wang K, Ning X and
Liu Z: Upregulated expression of MNX1-AS1 long noncoding RNA
predicts poor prognosis in gastric cancer. Bosn J Basic Med Sci.
19:164–171. 2019.
|
|
29
|
Cheng Y, Pan Y, Pan Y and Wang O: MNX1-AS1
is a functional oncogene that induces EMT and activates the
AKT/mTOR pathway and MNX1 in breast cancer. Cancer Manag Res.
11:803–812. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xue LP, Fu XL, Hu M, Zhang LW, Li YD, Peng
YL and Ding P: Rg1 inhibits high glucose-induced mesenchymal
activation and fibrosis via regulating miR-2113/RP11-982M15.8/Zeb1
pathway. Biochem Biophys Res Commun. 501:827–832. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang L, Chen Y, Bao C, Zhang X and Li H:
Eukaryotic initiation factor 4AIII facilitates hepatocellular
carcinoma cell proliferation, migration, and epithelial-mesenchymal
transition process via antagonistically binding to WD repeat domain
66 with miRNA-2113. J Cell Physiol. 235:8199–8209. 2020. View Article : Google Scholar
|
|
32
|
Wade M, Li YC and Wahl GM: MDM2, MDMX and
p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 13:83–96.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ren ZJ, Nong XY, Lv YR, Sun HH, An PP,
Wang F, Li X, Liu M and Tang H: Mir-509-5p joins the Mdm2/p53
feedback loop and regulates cancer cell growth. Cell Death Dis.
5:e13872014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fortunato O, Boeri M, Moro M, Verri C,
Mensah M, Conte D, Caleca L, Roz L, Pastorino L and Sozzi G:
Mir-660 is downregulated in lung cancer patients and its
replacement inhibits lung tumorigenesis by targeting MDM2-p53
interaction. Cell Death Dis. 5:e15642014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen Y, Wang DD, Wu YP, Su D, Zhou TY, Gai
RH, Fu YY, Zheng L, He QJ, Zhu H and Yang B: MDM2 promotes
epithelial-mesenchymal transition and metastasis of ovarian cancer
SKOV3 cells. Br J Cancer. 117:1192–1201. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu D, Niu X, Tao J, Li P, Lu Q, Xu A, Chen
W and Wang Z: MicroRNA-379-5p plays a tumor-suppressive role in
human bladder cancer growth and metastasis by directly targeting
MDM2. Oncol Rep. 37:3502–3508. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cai Y, Hao Y, Ren H, Dang Z, Xu H, Xue X
and Gao Y: miR-1305 inhibits the progression of non-small cell lung
cancer by regulating MDM2. Cancer Manag Res. 11:9529–9540. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shen J, Niu W, Zhou M and Zhang H, Ma J,
Wang L and Zhang H: MicroRNA-410 suppresses migration and invasion
by targeting MDM2 in gastric cancer. PLoS One. 9:e1045102014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tian XM, Luo YZ, He P, Li J, Ma ZW and An
Y: Inhibition of invasion and migration of prostate cancer cells by
miRNA-509-5p via targeting MDM2. Genet Mol Res. 16:232017.
View Article : Google Scholar
|
|
40
|
Moradimotlagh A, Arefian E, Valojerdi RR,
Ghaemi S, Adegani FJ and Soleimani M: MicroRNA-129 inhibits glioma
cell growth by targeting CDK4, CDK6, and MDM2. Mol Ther Nucleic
Acids. 19:759–764. 2020. View Article : Google Scholar : PubMed/NCBI
|
